240 related articles for article (PubMed ID: 19790238)
1. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
[TBL] [Abstract][Full Text] [Related]
2. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
5. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
6. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
7. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
8. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
10. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
11. [Antiandrogen withdrawal syndrome].
Akimoto S
Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
[TBL] [Abstract][Full Text] [Related]
12. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
14. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
[TBL] [Abstract][Full Text] [Related]
15. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
16. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
[TBL] [Abstract][Full Text] [Related]
17. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
19. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
20. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
